Graphite Bio leads this week's IPO squad, looking to turn the tide on sickle cell disease with gene editing
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Biotech’s IPO march continued earlier this week with Monte Rosa pricing on Thursday, and now Friday’s bunch heads to Nasdaq led by gene editing player Graphite Bio.
Located in South San Francisco, Graphite is going public Friday on the heels of a $238 million raise less than 10 months after getting started with a Series A. It’s been a rapid ascent, CEO Josh Lehrer told Endpoints News, but he feels the company is now at the point where it can focus both on drug development and further building out its platform.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.